Sol-Gel Technologies (SLGL) Accumulated Expenses (2016 - 2018)
Sol-Gel Technologies (SLGL) posted quarterly Accumulated Expenses of $1.0 million for Q4 2018, up 13.3% year-over-year from $910000.0 in Q4 2017, and down 29.77% quarter-over-quarter from $1.5 million in Q3 2018.
Analysis
Sol-Gel Technologies (SLGL) Accumulated Expenses (2016 - 2018) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Accumulated Expenses for 3 consecutive years, with $1.0 million the latest figure, recorded in Q4 2018.
- In Q4 2018, Accumulated Expenses rose 13.3% year-over-year to $1.0 million; the TTM figure through Dec 2018 stood at $1.0 million (up 13.3% YoY), while the FY2018 annual figure was $1.0 million, up 13.3% from the prior year.
- Accumulated Expenses retreated to $1.0 million in Q4 2018 per SLGL's latest filing, from $1.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.6 million in Q4 2016 and bottomed at $910000.0 in Q4 2017.
- Historically, Accumulated Expenses has averaged $1.7 million across 3 years, with a median of $1.5 million in 2018.
- Annual changes were most pronounced in 2017 — Accumulated Expenses tumbled 74.88% — and 2018, when it gained 13.3%.
- Sol-Gel Technologies' Accumulated Expenses stood at $3.6 million in 2016, then slumped by 74.88% to $910000.0 in 2017, then increased by 13.3% to $1.0 million in 2018.
- Business Quant data shows SLGL's Accumulated Expenses at $1.0 million in Q4 2018, $1.5 million in Q3 2018, and $1.5 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 1.03 Mn |
| Sep 30, 2018 | 1.47 Mn |
| Mar 31, 2018 | 1.53 Mn |
| Dec 31, 2017 | 910,000.00 |
| Dec 31, 2016 | 3.62 Mn |